Title says it all. Have never come across a biopharma LBO apart from Advent-Zentiva? Not sure if that was just an acquisition or a LBO as well. I know that PE investors typically seek to make returns within five years, something that has been difficult to do in the biopharma sector given this industry’s high failure rate, long clinical development times, and expensive late stage studies. Curious if anything has changed in the current market that would make specifically generic pharmaceuticals an attractive space for LBOs
Trending Content - Private Equity Forum
Career Resources
You said it all in your post -- generic drugs don't have to deal with development times, FDA approvals, establishing a market etc. Makes it way easier to lever up and generate a decent return. I can't imagine any traditional lender getting comfortable with a drug development story (I'm sure there's some weird niche-y exceptions).
Zentiva is generics and OTC as well
To add my 2 cents to the above, the risk associated with future cash flows from drugs in development is not compatible with an LBO in which you need to have a high certainty of the cash flows that the business will generate in order to apply as much leverage to it as you can at the point of acquisition. The risk associated with drugs in development is not normally distributed but much more binary in nature which is the main issue. PE funds are very active however in the specialty pharma, OTC and generics industries which are highly cash generative business and don't have the same development risk. Some recent acquisitions in the space are Nordic Capital / ADVANZ, Permira / Neuraxpharm, SERB / BTG Specialty etc
Porro vel maxime aut. Ut praesentium similique qui. Voluptas non maxime molestiae consequuntur distinctio deleniti.
Et sint veritatis consequatur commodi sequi explicabo. Suscipit eius aut molestiae quis modi. Et nisi aut placeat dolores atque perferendis nesciunt. Nesciunt illum quasi magni. Veniam sapiente mollitia quam quia rem et ea sequi. Alias ut deleniti sit nisi error.
Sed ex eligendi maiores fugit placeat molestias ullam. Sed dolor aspernatur nam commodi nostrum. Consequuntur officiis quae laudantium ullam. Nostrum dolor delectus iure nulla placeat cum. Et fugit repellat deleniti suscipit.
Ea eaque quae autem tenetur debitis voluptas sed. Reiciendis rerum minus aliquid hic accusamus voluptatibus. Odit officia esse ex qui libero dolorum. Et perferendis quaerat culpa. Delectus voluptatem et ut quod soluta. Voluptas ipsa consequuntur omnis aspernatur delectus aut. Sint adipisci soluta deserunt praesentium mollitia deleniti est deleniti.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...